Danielle Vugts
Overview
Explore the profile of Danielle Vugts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
139
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toyohara J, Vugts D, Kiss O, Todde S, Li X, Liu Z, et al.
EJNMMI Radiopharm Chem
. 2024 May;
9(1):42.
PMID: 38753262
Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Main Body: This selection...
2.
Wuensche T, Lyashchenko S, van Dongen G, Vugts D
EJNMMI Radiopharm Chem
. 2024 May;
9(1):40.
PMID: 38733556
Background: During the previous two decades, PET imaging of biopharmaceuticals radiolabeled with zirconium-89 has become a consistent tool in preclinical and clinical drug development and patient selection, primarily due to...
3.
Pouw J, Hashemi S, Huisman M, Wijngaarden J, Slebe M, Oprea-Lager D, et al.
J Immunother Cancer
. 2024 Feb;
12(2).
PMID: 38302416
Background: In patients with locally advanced unresectable non-small cell lung cancer (NSCLC), durvalumab, an anti-programmed cell death ligand-1 (PD-L1) antibody, has shown improved overall survival when used as consolidation therapy...
4.
Lumen D, Vugts D, Chomet M, Imlimthan S, Sarparanta M, Vos R, et al.
Bioconjug Chem
. 2022 Apr;
33(5):956-968.
PMID: 35442642
The recent advances in the production of engineered antibodies have facilitated the development and application of tailored, target-specific antibodies. Positron emission tomography (PET) of these antibody-based drug candidates can help...
5.
Korat S, Bidesi N, Bonanno F, Di Nanni A, Hoang A, Herfert K, et al.
Pharmaceuticals (Basel)
. 2021 Sep;
14(9).
PMID: 34577548
Neurodegenerative diseases such as Parkinson's disease (PD) are manifested by inclusion bodies of alpha-synuclein (α-syn) also called α-synucleinopathies. Detection of these inclusions is thus far only possible by histological examination...
6.
Vugts D, Trevorrow P
J Labelled Comp Radiopharm
. 2021 Sep;
64(13):489-491.
PMID: 34535913
No abstract available.
7.
Feiner I, Brandt M, Cowell J, Demuth T, Vugts D, Gasser G, et al.
Cancers (Basel)
. 2021 Sep;
13(17).
PMID: 34503276
Metallic radionuclides conjugated to biological vectors via an appropriate chelator are employed in nuclear medicine for the diagnosis (imaging) and radiotherapy of diseases. For the application of radiolabeled antibodies using...
8.
Aftimos P, Rolfo C, Rottey S, Barthelemy P, Borg C, Park K, et al.
Biomedicines
. 2021 Jul;
9(6).
PMID: 34200749
Dysregulation of MET signaling has been implicated in tumorigenesis and metastasis. ARGX-111 combines complete blockade of this pathway with enhanced tumor cell killing and was investigated in 24 patients with...
9.
Aime S, Al-Qahtani M, Behe M, Bormans G, Carlucci G, DaSilva J, et al.
EJNMMI Radiopharm Chem
. 2021 Mar;
6(1):13.
PMID: 33738618
Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Results: This commentary of...
10.
Al-Qahtani M, Behe M, Bormans G, Carlucci G, DaSilva J, Decristoforo C, et al.
EJNMMI Radiopharm Chem
. 2021 Jan;
6(1):5.
PMID: 33507426
Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to describe trends in the field. Results: This commentary of highlights has resulted in 19 different...